The clinical course of calpainopathy (LGMD2A) and dysferlinopathy (LGMD2B)

Neurological Research

Volumn 32, Issue 1, 2010, Pages 41-46

  Angelini, C ^a,b   Nardetto, L ^a,b   Borsato, C ^a   Padoan, R ^a   Fanin, M ^a,b   Nascimbeni, A C ^a,b   Tasca, E ^a,b  

^a Department of Neurosciences ^*  (Italy)

^b VENETIAN INSTITUTE OF MOLECULAR MEDICINE   (Italy)

Author keywords

Calpain 3; Clinical course; Dysferlin; LGMD

Indexed keywords

ADOLESCENT; ADULT; ANAMNESIS; ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL EXAMINATION; CONTROLLED STUDY; DISEASE COURSE; FEMALE; FUNCTIONAL ASSESSMENT; HUMAN; LIMB GIRDLE MUSCULAR DYSTROPHY; LIMB GIRDLE MUSCULAR DYSTROPHY TYPE 2A; LIMB GIRDLE MUSCULAR DYSTROPHY TYPE 2B; MALE; ONSET AGE; PHENOTYPE; PRESCHOOL CHILD; RATING SCALE; SCHOOL CHILD;

ADOLESCENT; ADULT; AGE OF ONSET; CHILD; CHILD, PRESCHOOL; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MUSCULAR DYSTROPHIES, LIMB-GIRDLE; NEUROLOGIC EXAMINATION; PHENOTYPE; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 77949457256     PISSN: 01616412     EISSN: None     Source Type: Journal    
DOI: 10.1179/174313209X380847     Document Type: Article

References (25)

1. Fanin M, Nascimbeni AC, Fulizio L, et al. The frequency of limb girdle muscular dystrophy 2A in northeastern Italy. Neuromuscul Disord 2005; 15: 218-224
2. Piluso G, Politano L, Aurino S, et al. Extensive scanning of the calpain-3 gene broadens the spectrum of LGMD2A phenotypes. J Med Genet 2005; 42: 686-693
3. Keira Y, Noguchi S, Minami N, et al. Localization of calpain 3 in human skeletal muscle and its alterations in limb-girdle muscular dystrophy 2A muscle. J Biochem 2003; 133: 659-664
4. Richard I, Broux O, Allamand V, et al. Mutations in the proteolytic calpain 3 cause limb-girdle muscular dystrophy type 2A. Cell 1995; 81: 27-40
5. Sorimachi H, Kinbara K, Kimura S, et al. Muscle-specific calpain, p94, responsible for limb girdle muscular dystrophy type 2A, associates with connectin through IS2, a p94-specific sequence. J Biol Chem 1995; 270: 31158-31162
6. Baghdiguian S, Martin M, Richard I, et al. Calpain 3 deficiency is associated with myonuclear apoptosis and profound perturbation of the IkBa/NF-kB pathway in LGMD type 2A. Nat Med 1999; 5: 503-511
7. Kramerova I, Kudryashova E, Venkatraman G, et al. Calpain 3 participates in sarcomere remodeling by acting upstream of the ubiquitin-proteasome pathway. Hum Mol Genet 2005; 14: 2125-2134
8. Walton JN, Nattrass FJ. On the classification, natural history and treatment of the myopathies. Brain 1954; 77: 169-231
9. Fanin M, Fulizio L, Nascimbeni AC, et al. Molecular diagnosis in LGMD2A: Mutation analysis or protein testing? Hum Mut 2004; 24: 52-62
10. Saenz A, Leturcq F, Cobo AM, et al. LGMD2A: Genotypephenotype correlations based on a large mutational survey on the calpain-3 gene. Brain 2005; 128: 732-742
11. Liu J, Aoki M, Illa I, et al. Dysferlin, a novel skeletal muscle gene, is mutated in Miyoshi myopathy and limb girdle muscular dystrophy. Nat Genet 1998; 20: 31-36
12. Bansal D, Miyake K, Vogel SS, et al. Defective membrane repair in dysferlin-deficient muscular dystrophy. Nature 2003; 423: 168-172
13. Mahjneh I, Passos-Bueno MR, Zatz M, et al. The phenotype of chromosome 2p-linked limb-girdle muscular dystrophy. Neuromuscul Disord 1996; 6: 483-490
14. Bushby KMD. Making sense of the limb-girdle muscular dystrophies. Brain 1999; 122: 1403-1420
15. Campanaro S, Romualdi C, Fanin M, et al. Gene expression profiling in dysferlinopathies using a dedicated muscle microarray. Hum Mol Genet 2002; 26: 3283-3298
16. Fanin M, Pegoraro E, Matsuda-Asada C, et al. Calpain-3 and dysferlin protein screening in limb-girdle muscular dystrophy and myopathy patients. Neurology 2001; 56: 660-665
17. Kawabe K, Goto K, Nishino I, et al. Dysferlin mutation analysis in a group of Italian patients with limb-girdle muscular dystrophy and Miyoshi myopathy. Eur J Neurol 2004; 11: 657-661
18. Pollitt C, Anderson LV, Pogue R, et al. The phenotype of calpainopathy: Diagnosis based on a multidisciplinary approach. Neuromuscul Disord 2001; 11: 287-296
19. Nguyen K, Bassez G, Bernard R, et al. Dysferlin mutations in LGMD2B, Miyoshi myopathy and atypical dysferlinopathies. Hum Mut 2005; 26: 165
20. Borsato C, Padoan R, Stramare R, et al. Limb-girdle muscular dystrophies type 2A and 2B: Clinical and radiological aspects. Basic Appl Myol 2006; 16: 17-25
21. Cenacchi G, Fanin M, Badiali de Giorgi L, et al. Ultrastructural changes in dysferlinopathy support defective membrane repair mechanism. J Clin Pathol 2005; 58: 190-195
22. Bartoli M, Roudaut C, Martin S, et al. Safety and efficacy of AAV-mediated calpain 3 gene transfer in a mouse model of limb girdle muscular dystrophy type 2A. Mol Ther 2006; 13: 250-259
23. Zaiss AK, Muruve DA: Immune response to adeno-associated virus vectors. Curr Gene Ther 2005; 5: 323-331
24. Bartoli M, Poupiot J, Vulin A, et al. AAV-mediated delivery of a mutated myostatin propeptide ameliorates calpain 3 but not alphasarcoglycan deficiency. Gene Ther 2007; 14: 733-740
25. Wenzel K, Zabojszcza J, Carl M, et al. Increased susceptibility to complement attack due to down-regulation of decay-accelerating factor/CD55 in dysferlin-deficient muscular dystrophy. J Immunol 2005; 175: 6219-16125